Matthew T. Hueman, MD, FACS

John P Murtha Cancer Center Logo FINAL

 

Matthew T. Hueman, MD, FACS
Lieutenant Colonel
, Medical Corps, US Army
Chief, Surgical Oncology, WRNMMC, Bethesda, MD
Assistant Professor of Surgery, Uniformed Services University, Bethesda, MD
Associate Program Director, NCC General Surgery, WRNMMC, Bethesda, MD

 

Matthew T. Hueman, MD, FACS Bio

Expertise

Pancreatic Cancer, Whipple Procedure, Peritoneal Surface Malignancy, Colon Cancer Liver Metastases, Gallbladder Cancer, Liver Resection, Gastric Cancer, Neuroendocrine tumors (Gastroenteropancreatic), Gastrointestinal Cancers, Breast Cancer, Thyroid Cancer, Hyperparathyroidism, Colorectal Cancer, General Surgery, Retroperitoneal Sarcomas, Sarcoma, Melanoma

Education

  • Bachelor of Science (1996), United States Military Academy (West Point, NY)
  • Doctor of Medicine (2000), Duke University School of Medicine (Durham NC)

Residencies

  • General Surgery (2006), Walter Reed Army Medical Center (Washington, DC)

Fellowship

  • Surgical Oncology (2009), The Johns Hopkins Hospital and Sidney Kimmel Cancer Center

Certifications

  • Surgery, American Board of Surgery (2007)
  • Surgical Oncology, Society of Surgical Oncology (2009)

Bio
Dr. Hueman graduated from the United States Military Academy at West Point, New York in 1996 and Duke University School of Medicine in 2000. He completed his residency training in General Surgery in 2006 at Walter Reed Army Medical Center and his fellowship training in Surgical Oncology in 2009 at the Johns Hopkins Hospital.

He has been a surgical oncologist since 2009 and has been at the Walter Reed National Military Medical Center from its very beginning in August 2011. He has been one of the Associate Program Directors of the National Capital Consortium's General Surgery Residency Training Program since July 2009 and is an Assistant Professor of Surgery at the Uniformed Services University. His previous assignments include Walter Reed Army Medical Center as an Attending Surgeon on the Teaching Staff in July 2006- June 2007 and in July 2009- August 2011, as well as at the National Naval Medical Center May 2010- August 2011. He is a Fellow of the American College of Surgeons and is a member of the Society of Surgical Oncology.

He has been deployed four times as a General Surgeon on a Forward Surgical Team (FST) (2006-07, 2009- 10, 2011-12, and 2014). He has deployed once in support of Operating Iraqi Freedom in Mosul, Iraq (serving on the 8th FST) and three times in support of Operating Enduring Freedom in Afghanistan (serving on the 8th FST, 67th FST, 102nd FST, 946th FST, 1980th FST, and 250th FST). In Afghanistan, he deployed in support of Regional-Command East at Forward Operating Bases Shank, Asadabad, and Sharana and in support of the Theater Reserve Force (2nd BN, 504th PIR, 1st BCT, 82nd Airborne Div) at Kandahar Air Field. He was the Chief Medical Officer of the 8th Forward Surgical Team while deployed in 2009-2010 at Forward Operating Base Shank, which at the time was the busiest location in the CENTCOM theater (highest number of treated injured patients per month).

Research Interests
Peptide-vaccine based immunotherapy of solid epithelial based tumors, such as breast cancer.

Selected Publications

  1. Hueman MT, Vollmer CM, Pawlik TM. Evolving Treatment Strategies for Gallbladder Cancer. Ann Surg Oncol. 2009 Aug;16(8):2101-15. Epub 2009 Jun 3.
  2. Gates JD, Clifton GT, Benavides LC, Sears AK, Carmichael MG, Hueman MT, Holmes JP, Jama YH, Mursal M, Zacharia A, Ciano K, Khoo S, Stojadinovic A, Ponniah S, Peoples GE. Circulating regulatory T cells (CD4+CD25+FOXP3+) decrease in breast cancer patients after vaccination with a modified MHC class II HER2/neu (AE37) peptide. Vaccine. 2010 Nov 3;28(47):7476-82. Epub 2010 Sep 19. PMID: 20858449
  3. Patil R, Clifton GT, Holmes JP, Amin A, Carmichael MG, Gates JD, Benavides LH, Hueman MT, Ponniah S, Peoples GE. Clinical and immunologic responses of HLA-A3+ breast cancer patients vaccinated with the HER2/neu-derived peptide vaccine, E75, in a phase IEvaluates the safety of a new treatment on patients with advanced cancer not effectively treated with standard care. There are specific requirements for phase I trials. Participation may be approved on a case-by-case basis./II clinical trial. J Am Coll Surg. 2010 Feb;210(2):140-7.
  4. Benavides LC, Gates JD, Carmichael MG, Patel R, Holmes JP, Hueman MT, Mittendorf EA, Craig D, Stojadinovic A, Ponniah S, Peoples GE. The Impact of HER2/neu Expression Level on Response to the E75 Vaccine: From U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Can Res. 2009 Apr 7. [Epub ahead of print]
  5. Gates JD, Carmichael MG, Benavides LC, Holmes JP, Hueman MT, Woll MM, Ioannides CG, Robson CH, McLeod DG, Ponniah S, Peoples GE. Long-term Follow-up Assessment of a HER2/neu Peptide (E75) Vaccine for the Prevention of Recurrence in High-Risk Prostate Cancer Patients. J Am Coll Surg. 2009 Feb;208(2):193-201.
  6. Holmes JP, Gates JD, Benavides LC, Hueman MT, Carmichael MG, Patil R, Craig D, Mittendorf EA, Stojadinovic A, Ponniah S, Peoples GE. Optimal dose and schedule of an HER-2/neu (E75) peptide vaccine to prevent breast cancer recurrence: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer. 2008 Aug 25; 113(7):1666-1675. [Epub ahead of print]
  7. Holmes JP, Benavides LC, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Murray JL, Amin A, Craig D, von Hofe E, Ponniah S, Peoples GE. Results of the First Phase I Clinical Trial of the Novel Ii-Key Hybrid Preventive HER2/neu Peptide (AE37) Vaccine: United States Military Cancer Institute Clinical Trials Group Study I-03. J Clin Oncol. 2008 Jul 10;26(20):3426-33.
  8. Amin A, Benavides LC, Holmes JP, Gates JD, Carmichael MG, Hueman MT, Mittendorf EA, Storrer CE, Jama YH, Craig D, Stojadinovic A, Ponniah S, Peoples GE. Assessment of immunologic response and recurrence patterns among patients with clinical recurrence after vaccination with a preventive HER2/neu peptide vaccine: from US Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Cancer Immunol Immunother. 2008 Apr 8. [Epub ahead of print]
  9. Peoples GE, Holmes JP, Hueman MT, Mittendorf EA, Amin A, Khoo S, Dehqanzada ZA, Gurney JM, Woll MM, Ryan GB, Storrer CE, Craig D, Ioannides CG, Ponniah S. Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02. Clin Cancer Res. 2008 Feb 1;14(3):797-803.
  10. Stojadinovic A, Mittendorf EA, Holmes JP, Amin A, Hueman MT, Ponniah S, Peoples GE. Quantification and Phenotypic Characterization of Circulating Tumor Cells for Monitoring Response to a Preventive HER2/neu Vaccine-Based Immunotherapy for Breast Cancer: A Pilot Study. Ann Surg Oncol. 2007 Dec;14(12):3359-68. Epub 2007 Sep 29.
  11. Hueman MT, Dehqanzada Z, Novak TE, Gurney JM, Woll MM, Ryan GB, Storrer CE, Fisher C, McLeod DG, Moul JW, Ioannides CG, Ponniah S, Peoples GE. Phase I Clinical Trial of a HER2/neu Peptide (E75) Vaccine for the Prevention of Prostate-Specific Antigen Recurrence in High-Risk Prostate Cancer Patients. Clin Cancer Res. 2005 Oct; 11(20): 7470-79.
  12. Hueman MT, Stojadinovic A, Storrer CE, Dehqanzada Z, Gurney JM, Shriver CD, Ponniah S, Peoples GE. Analysis of CD4 and CD8 T cell Populations Induced by a HER2/neu Peptide (E75) Vaccine in Breast Cancer Patients. Cancer Immunol Immunother. 2007 Feb;56(2):135-46. Epub 2006 Jun 17.
  13. Hueman MT, Stojadinovic A, Storrer CE, Gurney JM, Shriver CD, Ponniah S, Peoples GE. Levels of Circulating Regulatory CD4+ CD25+ T Cells Are Decreased in Breast Cancer Patients After Vaccination with a HER2/neu Peptide (E75) Vaccine. Breast Cancer Res Treat. 2006 Jul;98(1):17- 29. Epub 2006 Jun.
  14. Peoples GE, Gurney JM, Hueman MT, Woll MM, Ryan GB, Storrer CE, Fisher CF, Shriver CD, Ioannides CG, Ponniah S. Clinical Trial Results of a HER2/neu (E75) Vaccine to Prevent Recurrence in High Risk Breast Cancer Patients. J Clin Oncol. 2005 Oct; 23(30): 7536-45.
  15. Dehqanzada ZA, Storrer CE, Hueman MT, Foley RJ, Harris KA, Jama YH, Kao T, Shriver CD, Ponniah S, Peoples GE. Correlations between Serum Monocyte Chemotactic Protein-1 Levels, Clinical Prognostic Factors, and HER-2/neu Vaccine-Related Immunity in Breast Cancer Patients. Clin Cancer Res. 2006 Jan; 12(2): 478-86.

Last Updated 11/4/2019